Roughness and Level of Product Protection

The main pharmaco-therapeutic effects: Hemostatic toddlers . The main pharmaco-therapeutic effects: Hemostatic. Pharmacotherapeutic group: V02VD02 - hemostatic toddlers The main pharmaco-therapeutic effects: Hemostatic. Indications for use drugs: treatment of hemophilia A, a temporary compensation of the missing clotting factor to treat or prevent the occurrence of bleeding, prevention of bleeding, surgical intervention in patients with hemophilia. Contraindications to the use of drugs: hypersensitivity to the drug. Method of production of drugs: concentrate antyhemofilnoho factor of 250 MO/500 IU and 1000 IU vial. Pharmacotherapeutic group: V02V002 - hemostatic Nasotracheal Coagulation factors. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia A (congenital lack of factor VIII), including in surgical operations in patients with hemophilia A. in the volume of 5 ml, 10 ml. Contraindications to the use of drugs: not known. Pharmacotherapeutic group: V02VD02 - hemostatic agents. Pharmacotherapeutic group: V02VD04 - hemostatic agents. Method of production of drugs: lyophilized powder for Mr infusion / etc 'yehtsiy toddlers IU, 500 IU or 1000 IU.